Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study

Orringer, 1999, Transhiatalesophagectomy: clinical experience and refinements, Ann Surg, 230, 392, 10.1097/00000658-199909000-00012

Wong, 2006, Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus, Cochrane Database Syst Rev, 2092

Van den Eynde, 2011, Epidermal growth factor receptor targeted therapies for solid tumours, Acta Clin Belg, 66, 10, 10.1179/ACB.66.1.2062508

Lordick, 2006, Current treatment approach to locally advanced esophageal cancer: is resection mandatory?, Future Oncol, 2, 717, 10.2217/14796694.2.6.717

Kawaguchi, 2007, Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma, Br J Cancer, 97, 494, 10.1038/sj.bjc.6603885

Hanawa, 2006, EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus, Int J Cancer, 118, 1173, 10.1002/ijc.21454

Ilson, 2011, A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus, Cancer, 117, 1409, 10.1002/cncr.25602

Sutter, 2006, Targeting the epidermal growth factor receptor by erlotinib (Tarceva) for the treatment of esophageal cancer, Int J Cancer, 118, 1814, 10.1002/ijc.21512

Dobelbower, 2006, Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I study, Anticancer Drugs, 17, 95, 10.1097/01.cad.0000185178.26862.4c

Li, 2010, Phase II study of concurrent chemoradiation in combination with erlotinib for locally advanced esophageal carcinoma, Int J Radiat Oncol Biol Phys, 78, 1407, 10.1016/j.ijrobp.2009.10.012

Yano, 1991, Immunohistologic detection of the epidermal growth factor receptor in human esophageal squamous cell carcinoma, Cancer, 67, 91, 10.1002/1097-0142(19910101)67:1<91::AID-CNCR2820670118>3.0.CO;2-A

Shepherd, 2005, Erlotinib in previously treated non-small-cell lung cancer, N Engl J Med, 353, 123, 10.1056/NEJMoa050753

Ku, 2010, Esophagogastric cancer: targeted agents, Cancer Treat Rev, 36, 235, 10.1016/j.ctrv.2009.12.009

Shimizu, 2005, Clinical evaluation of low-dose cisplatin and 5-fluorouracil as adjuvant chemoradiotherapy for advanced squamous cell carcinoma of the esophagus, Hiroshima J Med Sci, 54, 67

Kumekawa, 2006, Late toxicity in complete response cases after definitive chemoradiotherapy for esophageal squamous cell carcinoma, J Gastroenterol, 41, 425, 10.1007/s00535-006-1771-8

Ishikura, 2003, Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus, J Clin Oncol, 21, 2697, 10.1200/JCO.2003.03.055

Morota, 2009, Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma, Int J Radiat Oncol Biol Phys, 75, 122, 10.1016/j.ijrobp.2008.10.075

Devaraju, 2009, Risk scoring for predicting mucositis in Indian patients with esophageal carcinoma receiving concurrent chemoradiotherapy, Gastrointest Cancer Res, 3, 4

Rodriguez, 2010, A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer, J Thorac Oncol, 5, 229, 10.1097/JTO.0b013e3181c5e334

Janmaat, 2006, Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients, J Clin Oncol, 24, 1612, 10.1200/JCO.2005.03.4900

Tew, 2005, Phase II trial of erlotinib for second-line treatment in advanced esophageal cancer, Proc Gastrointest Am Soc Clin Oncol Symp, 85, 5a